Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has signed an exclusive agreement with US-based Myriad Genetics to bring cancer-risk assessment diagnostic tests to India. The partnership will allow Zydus to offer Myriad's established genetic testing technology in the Indian market on an exclusive basis. This move expands Zydus's footprint beyond pharmaceuticals into the growing preventive and personalised diagnostics space. Myriad Genetics is a well-known player in genetic testing for cancer risk. The collaboration could help address the rising demand for early cancer screening and genetic counselling in India.
Positive for shareholders — adds a new high-growth revenue stream in diagnostics and gives Zydus exclusive access to proven US technology, though near-term financial impact is likely modest. Could support the stock narrative around diversification and innovation.